{"filings":[{"id":1895516,"accession_number":"0001730430-26-000031","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-07-28T11:33:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $243.6M (+55% YoY); raises FY2026 guidance to $980-995M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $243.6M in Q2 2026, ~55% YoY growth; ~21% of 14,000 multiple-recurrence patients on therapy.","2026 ARCALYST net revenue guidance raised to $980-995M from prior $930-945M.","Net income $25.4M vs $17.8M in Q2 2025; cash $525.9M, no debt.","KPL-387 Phase 2 data: median time to treatment response 4.0 days at 300 mg SC monthly; Phase 3 PASTORALE enrolling.","KPL-1161 preclinical; Phase 1 expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":747676,"accession_number":"0001730430-26-000029","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-29T20:35:27+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.","PricewaterhouseCoopers LLP approved as both UK statutory auditor and US independent auditor with overwhelming votes.","Advisory vote on named executive officer compensation passed with 48.1M for and 1.3M against.","All eight proposals, including director elections, auditor appointments, and remuneration reports, were duly passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669556,"accession_number":"0001730430-26-000025","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-26T20:55:02+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.","Waiver is irrevocable and unconditional; amendment requires at least 75% shareholder approval.","Deed prohibits circumvention; any conversion attempt violating the cap is void ab initio.","Other shareholder rights (voting, dividends, capital return) remain unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95055,"accession_number":"0001730430-26-000021","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.","Decision not due to any disagreement with the company on operations, policies, or practices.","Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.","Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.","Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95054,"accession_number":"0001730430-26-000017","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.","2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.","Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.","KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.","Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":214266000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107855,"accession_number":"0001730430-26-000014","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.","Net income $14.2M Q4, $59.0M FY 2025 vs net loss of $8.9M/$43.2M in prior-year periods.","Cash, cash equivalents & short-term investments $414.1M, no debt, up from $243.6M.","2026 ARCALYST revenue guidance $900-$920M; company expects positive annual cash flow from operations.","KPL-387 Phase 2/3 recurrent pericarditis data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":677564000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107854,"accession_number":"0001730430-26-000010","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa appoints Ross Moat as COO and Eben Tessari as Chief Strategy Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ross Moat promoted to COO effective Jan 10, 2026; will oversee commercial and functional operations.","Eben Tessari appointed Chief Strategy Officer effective Jan 10, 2026; adds AI initiatives to strategy and BD.","No changes to compensation for either executive in connection with the appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107853,"accession_number":"0001730430-26-000005","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.","2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.","Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.","KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.","~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124252,"accession_number":"0001104659-25-102834","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.","ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.","2025 revenue guidance raised to $670-675M from prior $625-640M.","KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.","Prescribers >3,825; average therapy duration ~32 months."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":475437000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140932,"accession_number":"0001104659-25-086689","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiniksa posts September 2025 investor presentation, no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation posted on investors.kiniksa.com on September 3, 2025.","Presentation expected to be used in meetings with investors and analysts.","No financial results, guidance, or specific corporate events announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140931,"accession_number":"0001104659-25-071413","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).","2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.","Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.","KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.","Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":294582000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158691,"accession_number":"0001104659-25-056665","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.","Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).","Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.","Phase 2 data expected in second half of 2026.","Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158690,"accession_number":"0001104659-25-055990","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders elect all director nominees and approve all 13 proposals at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Stephen R. Biggar received 15.3M against votes, Felix J. Baker 12.3M against.","Say-on-pay (Prop 10) passed with 49.1M for, 550.7K against.","Authority to allot shares up to ~35% of share capital (Prop 11) passed: 41.2M for, 11.2M against.","Disapplication of pre-emption rights (Prop 12) passed: 40.7M for, 11.7M against.","Preference share redemption to create distributable reserves (Prop 13) passed with 52.4M for, 23.2K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158689,"accession_number":"0001104659-25-040641","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.","Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.","KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.","Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.","Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":137785000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158688,"accession_number":"0001104659-25-038041","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.","CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.","Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.","If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.","The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177080,"accession_number":"0001104659-25-016725","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.02","2.02","2.05","9.01"],"status":"ready","headline":"Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).","2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.","Terminated MedImmune license for mavrilimumab; effective May 22, 2025.","Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.","Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":423239000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177079,"accession_number":"0001104659-25-002858","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.","2025 ARCALYST net product revenue guidance: $560M to $580M.","Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.","Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.","Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193855,"accession_number":"0001104659-24-112034","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.","Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.","Over 2,550 prescribers since launch; average therapy duration ~27 months.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.","Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":300703000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193854,"accession_number":"0001104659-24-106690","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa appoints M. Cantey Boyd to Board, increasing size to 10 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 9 to 10; Boyd appointed as Class III director.","Boyd is a Managing Director at Baker Bros. Advisors LP, a life sciences investment firm.","She will serve on Compensation Committee; receives standard non-employee director compensation.","No material transactions between Boyd and the company; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210192,"accession_number":"0001104659-24-081717","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.","Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.","2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.","Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":188489000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228451,"accession_number":"0001104659-24-076282","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K12B","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","3.01","3.02","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.","Shareholders received one-for-one exchange of shares; ~40.4M Class A, 1.8M B, 12.8M A1, 16.1M B1 ordinary shares issued.","Class A Ordinary Shares continue trading on Nasdaq under symbol KNSA as of June 28, 2024.","Same executive officers and directors continue; indemnification agreements and equity plans assumed.","Depositary receipts issued for shares not directly eligible for DTC transfer to avoid UK stamp duty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228456,"accession_number":"0001104659-24-074763","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.","Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.","PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.","Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228455,"accession_number":"0001104659-24-071787","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kiniksa gets Bermuda court sanction for redomiciliation to UK, effective ~June 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bermuda Supreme Court sanctioned the scheme of arrangement on June 14, 2024.","Shareholders approved the redomiciliation at a court-ordered meeting on June 5, 2024.","Redomiciliation from Bermuda to UK expected to take effect on or around June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228454,"accession_number":"0001104659-24-068694","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders approve redomiciliation scheme; court sanction hearing set for June 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scheme of arrangement approved by 61,460,949 votes for, 501,355 against, 274,060 abstained.","Supreme Court of Bermuda sanction hearing expected on or around June 14, 2024 at 9:30 a.m. AST.","At annual meeting, directors Felix J. Baker, Tracey L. McCain, Kimberly J. Popovits re-elected; auditor PwC ratified; say-on-pay passed.","Redomiciliation meeting was held immediately after annual meeting per Bermuda court order dated April 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228453,"accession_number":"0001104659-24-050335","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.","Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.","Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.","Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.","About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":79858000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228452,"accession_number":"0001104659-24-042231","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.","Cohort 4 RA data: abiprubart 400 mg SC monthly showed DAS28-CRP LS mean difference -0.58 vs placebo (p=0.109, not significant).","Statistically significant ~40% reduction in Rheumatoid Factor in Cohort 4 (p=0.0003); pooled analysis DAS28-CRP diff -0.52 (nominal p=0.010).","Abiprubart development in Sjogren's fully funded through Phase 3; company expects to remain cash flow positive annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247134,"accession_number":"0001104659-24-040847","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiniksa proposes redomicile from Bermuda to UK via scheme of arrangement; expects completion H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposes to change principal holding company incorporation from Bermuda to the UK by scheme of arrangement.","Shares exchanged 1:1 for new UK company shares; continues trading on Nasdaq under ticker KNSA.","Cites improved tax treaty access and protection from OECD/Bermuda tax initiatives as key reasons.","No material impact on financial results expected; completion targeted for second half 2024.","Convening hearing before Bermuda Supreme Court set for April 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247133,"accession_number":"0001104659-24-028472","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.","2024 ARCALYST revenue guidance $360-380M, ~59% YoY growth at midpoint.","Q4 net income $25.2M vs $4.5M YoY; cash $206.4M, no debt, funds operations into at least 2027.","Abiprubart Phase 2 Cohort 4 data and new development indication expected April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":270259000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247132,"accession_number":"0001104659-24-001149","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.","2024 ARCALYST net product revenue guidance set at $360M-$380M.","Abiprubart Phase 2 RA trial met primary endpoint at 5 mg/kg weekly dose (p=0.0487); 5 mg/kg biweekly missed.","Cash, equivalents, and short-term investments $206.3M expected to fund operations into at least 2027.","~9% of target 14,000 multiple-recurrence pericarditis patients on ARCALYST; salesforce expanded to ~85 reps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264575,"accession_number":"0001104659-23-112750","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).","Net loss $13.9M vs net income $224.1M in Q3 2022 (prior year included $65.7M license revenue).","Cash $201.1M, no debt; expected to fund operations into at least 2027.","KPL-404 Phase 2 RA data from Cohorts 1-3 expected Q1 2024; Cohort 4 data expected Q2 2024.","FY2023 ARCALYST revenue guidance $220-230M, tracking to high end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":186864000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281807,"accession_number":"0001104659-23-083629","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).","Net income $15.0M vs net loss $20.0M YoY; includes $16.2M tax benefit from valuation allowance release.","2023 ARCALYST revenue guidance raised to $220-230M from $200-215M; cash runway extended into at least 2027.","Over 1,250 prescribers have written ARCALYST; average therapy duration ~20 months; 45% of patients restarted within 8 weeks.","KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024; $15.0M milestone from Genentech vixarelimab agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":119818000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300777,"accession_number":"0001104659-23-068966","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa annual meeting elects three directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart elected as Class II directors with majority vote.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 (44.8M for, 23.6K against).","Non-binding advisory vote on executive compensation approved (40.4M for, 1.3M against).","All proposals passed; no annual meeting surprises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300776,"accession_number":"0001104659-23-054807","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).","Net loss improved to $12.3M from $25.2M YoY; total revenue $48.3M vs $32.2M.","Cash & short-term investments $187.5M, no debt; cash runway now expected into at least 2026.","Final cohort of KPL-404 Phase 2 RA trial enrolling; data expected 1H 2024.","Over 1,000 prescribers written ARCALYST scripts since launch; payer approval rate >90%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":48345000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320714,"accession_number":"0001104659-23-031371","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Kiniksa reveals no exposure to Silicon Valley Bank; no deposits or securities held","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Kiniksa confirmed it did not hold cash deposits or securities with SVB.","Company also stated it has no business relationship with SVB.","Disclosure made on March 10, 2023, amid SVB liquidity crisis.","This voluntary FD disclosure reassures investors of zero SVB exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320713,"accession_number":"0001104659-23-026402","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.","Total revenue $61.9M Q4, $220.2M full-year; license revenue from Roche/Genentech and Huadong.","Net income $4.5M Q4 vs loss $36.3M; full-year net income $183.4M includes $172.3M tax benefit.","Cash $190.6M, no debt; expects cash to fund operations into at least 2025.","KPL-404 Phase 2 RA trial advancing; efficacy data expected first half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":220180000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320712,"accession_number":"0001104659-23-002072","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).","Year-end 2022 cash, equivalents and ST investments $190.4M, funding into at least 2025.","Greater than 800 prescribers for recurrent pericarditis; 22% have prescribed for 2+ patients.","Payer approval rate >90%; approx 45% of patients who discontinued ARCALYST restarted therapy.","KPL-404 Phase 2 RA trial: 2 of 3 cohorts enrolled; proof-of-concept data expected 1H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338844,"accession_number":"0001104659-22-113204","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.","Total revenue $99.1M, including $65.7M from vixarelimab license with Genentech.","Net income $224.1M vs net loss $30.5M YoY; includes $177.4M tax benefit from valuation allowance release.","Cash and equivalents $200.7M, no debt; expected to fund operations into at least 2025.","RHAPSODY LTE data: rilonacept beyond 18 months reduced recurrence risk 98.2% (HR=0.018, p<0.0001)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":158296000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356212,"accession_number":"0001104659-22-085446","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.","ARCALYST Q2 2022 net revenue $27.0M (vs. $7.7M Q2 2021); full-year 2022 guidance reaffirmed at $115-130M.","Q2 net loss narrowed to $20.0M (vs. $41.6M), with cash $138.2M and no debt; cash runway into 2025 after deal close.","Phase 2b vixarelimab trial in prurigo nodularis screening complete; data disclosure delayed beyond H2 2022.","Proceeds to fund cardiovascular pipeline expansion; ~20 additional ARCALYST sales reps planned in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374581,"accession_number":"0001104659-22-076309","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders elect three Class I directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanj K. Patel, Thomas R. Malley, Richard S. Levy elected as Class I directors with 33.3M, 31.5M, 34.4M votes for respectively.","Ratification of PricewaterhouseCoopers as auditor for FY2022 approved: 45.3M for, 33k against, 27k abstained.","Advisory say-on-pay proposal approved: 41.5M for, 333k against, 56.6k abstained; 3.45M broker non-votes.","Annual meeting held June 29, 2022; quorum present with Class A and Class B shares voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374580,"accession_number":"0001104659-22-055055","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q1 2022 ARCALYST net revenue $22.2M; net loss narrows to $25.2M; FY2022 guidance $115-130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net revenue $22.2M in Q1 2022 versus $0 in Q1 2021; total revenue $32.2M including $10M collaboration revenue.","Net loss $25.2M, improved from $49.5M loss in Q1 2021; cash $145.6M, no debt.","Full-year 2022 ARCALYST net revenue guidance $115M-$130M; cash expected to fund operations into at least 2024.","Strategic collaboration with Huadong Medicine for Asia Pacific rights: $22M upfront, up to $640M milestones, tiered royalties.","Over 400 prescribers for ARCALYST since launch; ~95% coverage approval; ~60% patients retained on therapy through Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":32189000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393069,"accession_number":"0001104659-22-025377","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).","ARCALYST net revenue $18.7M Q4 2021, $38.5M FY2021; collaboration achieved profitability in Q4.","FY2022 ARCALYST net revenue guidance $115-130M; cash $182.2M, no debt, funded into 2024.","No Phase 3 for mavrilimumab in giant cell arteritis; vixarelimab Phase 2b data in prurigo nodularis expected H2 2022.","Net loss $36.3M Q4 2021 vs $53.7M Q4 2020; full-year net loss $157.9M vs $161.4M in 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393068,"accession_number":"0001104659-22-002543","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.","Mavrilimumab Phase 3 in COVID-19 ARDS did not meet primary endpoint; company evaluating next steps.","Full-year 2022 ARCALYST net revenue guidance to be provided with Q4 and full-year 2021 financial results.","Vixarelimab Phase 2b data in prurigo nodularis expected in second half of 2022.","KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393067,"accession_number":"0001104659-22-000429","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kiniksa appoints Eben Tessari as SVP, Chief Operating Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eben Tessari promoted to COO effective Jan 3, 2022; previously SVP Chief Business Officer.","New employment agreement provides $444,960 base salary and 40% target annual bonus.","Severance includes 9 months base salary plus $16,500 lump sum and 12-month equity acceleration.","Tessari also subject to existing invention, non-disclosure, non-competition agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411527,"accession_number":"0001104659-21-132088","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.","Net loss of $30.5M improved from $43.8M in Q3 2020; operating expenses $42.8M.","Cash and investments $200.2M, no debt; cash expected to fund operations into 2023.","Mavrilimumab Phase 3 in COVID-19 ARDS data expected Q1 2022; vixarelimab Phase 2b data in prurigo nodularis expected 2H 2022.","Over 200 physicians prescribed ARCALYST for recurrent pericarditis since approval; >190M lives covered."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":19799000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430281,"accession_number":"0001104659-21-099173","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.","Net loss $41.6M vs $37.5M YoY; operating expenses $48.3M (incl $5.7M stock comp).","Cash and investments $225.9M, no debt; expects to fund operations into 2023.","Q3 2021 ARCALYST revenue guidance $9-10M; pipeline: mavrilimumab Ph3 data Q1 2022, KPL-404 Ph2 start Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":7704000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430280,"accession_number":"0001104659-21-089476","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders elect directors, ratify auditor, approve exec pay, adopt annual say-on-pay vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Felix J. Baker, Tracey L. McCain, Kimberly J. Popovits elected as Class III directors with ~32.8M, 35.9M, 35.8M votes for, respectively.","PricewaterhouseCoopers LLP ratified as auditor for FY2021: 44.3M for, 66K against, 21K abstain.","Non-binding advisory vote on executive compensation approved: 40.6M for, 625K against, 24.7K abstain.","Shareholders recommended annual say-on-pay votes (40.9M for one year); board adopts annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}